Association of the S267F variant on NTCP gene and treatment response to pegylated interferon in patients with chronic hepatitis B: a multicentre study.

Abstract

BACKGROUND Sodium taurocholate co-transporting polypeptide (NTCP) is a cell receptor for hepatitis B virus (HBV). The S267F variant on the NTCP gene is inversely associated with the chronicity of HBV infection, progression to cirrhosis and hepatocellular carcinoma in East Asian populations. This aim of this study was to determine whether the S267F variant was associated with response to pegylated interferon (Peg-IFN) in patients with chronic HBV infection. METHODS Two hundred and fifty-seven patients with chronic HBV, treated with Peg-IFN for 48 weeks, were identified from 13 tertiary hospitals included in the hepatitis B database of the Thai Association for the Study of the Liver (THASL). RESULTS Of these, 202 patients were infected with HBV genotype C (84.9%); 146 patients were HBeAg positive (56.8%). Genotypic frequencies of the S267F polymorphism were 85.2%, 14.8%, and 0% for the GG, GA, and AA genotypes, respectively. S267F GA was associated with sustained alanine aminotransferase (ALT) normalization (OR = 3.25, 95% CI: 1.23-8.61, p = 0.02) in HBeAg-positive patients. Patients with S267F variant tended to have more virological response, sustained response with HBsAg loss at 24 weeks following Peg-IFN treatment. There was no association between the S267F variant and improved patient outcomes in HBeAg-negative patients. CONCLUSIONS The S267F variant on the NTCP gene is independently associated with sustained normalization of ALT following treatment with Peg-IFN in patients with HBV infection who are HBeAg-positive. The findings of this study provide additional support for the clinical significance of the S267F variant of NTCP beyond HBV entry.

DOI: 10.3851/IMP3179

Cite this paper

@article{Thanapirom2017AssociationOT, title={Association of the S267F variant on NTCP gene and treatment response to pegylated interferon in patients with chronic hepatitis B: a multicentre study.}, author={Kessarin Thanapirom and Sirinporn Suksawatamnuay and Wattana Sukeepaisarnjaroen and Sombat Treeprasertsuk and Tawesak Tanwandee and Phunchai Charatcharoenwitthaya and Satawat Thongsawat and Apinya Leerapun and Teerha Piratvisuth and Rattana Boonsirichan and Chalermrat Bunchorntavakul and Chaowalit Pattanasirigool and Bubpha Pornthisarn and Supoj Tuntipanichteerakul and Ekawee Sripariwuth and Woramon Jeamsripong and Teeranan Sanpanjit and Yong Poovorawan and Piyawat Komolmit}, journal={Antiviral therapy}, year={2017} }